Characteristics of Le^y Antigen

The presence of sugar chains on the cell surface is one of the important features of cells, where sugars are covalently bound to proteins or lipids to form glycol complexes. It has been found that the surface glycan chains undergo significant changes during cell deterioration. These changes have also become the hallmark of a new generation of tumorigenesis. Le^y antigen is a terminal oligosaccharide of certain glycoproteins and glycolipids and is a bis-mannofuran oligosaccharide. Le^y antigen is found in epithelial tissues, and when these tissues become cancerous, its expression is significantly higher, at the same time, the expression of Le^y antigen increases with the enhancement of cellular deterioration. Currently, molecular targeted therapy is a useful direction for antitumor therapy. Therefore, using Le^y as a targeting molecule to treat tumors is a useful approach.

Fig.1 Structures of Le^y derivatives 1 and 2. (Li, et al., 2019)

Tumor-Associated Le^y Antigen Production Service at CD BioGlyco

CD BioGlyco is well-established in vaccine development and antigen production. We have established a Glyco™ Vaccine Development Platform and provide tumor-associated Le^y antigen production services as well as vaccine development services.

For Le^y antigen production, we offer methods including but not limited to.

• One-pot glycosylation

In this method, CD BioGlyco consists of a monosaccharide thioglycoside as a glycosylation acceptor, with the addition of an organic reagent and a fucoidan glycosylation donor, which promotes stereoselective glycosylation, passing through a disaccharide intermediate thus completing the synthesis of Le^y. In this process, we practice a protection-deprotection operation to avoid side reactions.

Highlight: Elimination of intermediate separation and characterization processes makes the synthesis efficient and scalable.

• Reverse synthesis

The method provided by CD BioGlyco involves the introduction of oxidized azide sequences, regioselective protection, isomeric carbon activation, glycosidic bond formation, and deprotection of lactic acid as the raw material to complete the synthesis of Le^y antigens.

Highlight: Efficient and direct.

After synthesizing the Le^y antigen, CD BioGlyco uses it in the development of tumor-associated vaccines and detects the immune response it generates.

Fig.2 Methods of producing Le^y antigen. (CD BioGlyco)

Applications

• Le^y antigen serves as a targeting molecule that can be used in the development of anti-tumor drugs.
• Le^y antigen is overexpressed on tumor cells. it can be used in research for anti-tumor vaccines.

Advantages

• We have a wide range of Le^y synthesis methods to provide custom production solutions for our clients.
• We produce Le^y antigen with high efficiency and purity, which is suitable for use in the development of tumor-related vaccines.

CD BioGlyco has a professional research team and has constructed a complete vaccine development platform. We have rich experience in vaccine development and antigen production. Among them, in the production of tumor-related antigens, we have a variety of production methods and provide production solutions that suit clients' situations. Please feel free to contact us for more detailed information.

Reference

1. Li, Q.J.; et al. Synthesis of Lewis Y analogs and their protein conjugates for structure-immunogenicity relationship studies of Lewis Y antigen. The Journal of Organic Chemistry. 2019, 84(21): 13232-13241.